Enfusion — Q2 2024 Earnings Presentation
25 slides from Enfusion's earnings presentation, Aug 6, 2024
Slide 1: Enfusion 2Q 2024 Shareholder Letter
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Enfusion 2Q 2024 Shareholder Letter August 2024
Slide 2: Disclaimer: Forward-Looking Statements
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Disclaimer 2 Forward-Looking Statements Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933 (
Slide 3: Dear Shareholders
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 3 Dear Shareholders, Enfusion performed well in the second quarter, generating revenue of $49.5M, translating to 16% year over year growth and a year over year expansion of adjusted EBITDA margin. We won 39 new accounts this quarter,
Slide 4: Our Mission
PROPRIETARY AND CONFIDENTIAL PROPRIETARY ©2023 ENFUSION. ALL RIGHTS RESERVED. 2024 ENFUSION. ALL RIGHTS RESERVED. 4 Our Mission To power all investment workflows with our unparalleled technology, relentless innovation, and dedicated focus on clients All Workflows Durable Financial Profile Relentless
Slide 5: Enfusion is a Unique Collaboration Platform
PROPRIETARY AND CONFIDENTIAL PROPRIETARY ©2023 ENFUSION. ALL RIGHTS RESERVED. 2024 ENFUSION. ALL RIGHTS RESERVED. Compliance Trading Risk Operations Investor Relations Business Development Portfolio Managers Research Enfusion is a Unique Collaboration Platform Our SaaS architecture & product roadmap
Slide 6: Time to disrupt traditional asset management: $25B TAM
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 6 It is our time to disrupt the traditional asset management segment the same way we disrupted the alternatives segment Untapped Upside Potential: $25B TAM $25B $15.3B $1.2B $1.3B $7.2B Private Equity & Private Credit Firms Equity Hed
Slide 7: Evolution of the Enfusion Product: 2024
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. OEMS & Compliance Portfolio Management Solutions Portfolio Construction Workbench Decision Analytics Portfolio Analytics Reporting Reference Data Book of Record Managed Services Back-office Accounting and Operations Future roadmap Inc
Slide 8: The Perfect Storm: Why Enfusion Wins
PROPRIETARY AND CONFIDENTIAL PROPRIETARY ©2023 ENFUSION. ALL RIGHTS RESERVED. 2024 ENFUSION. ALL RIGHTS RESERVED. 8 The Perfect Storm: Why Enfusion Wins Built with multi-tenant SaaS architecture from day one Enfusion’s History Trailblazing technology foundational to future growth Client’s Race to Cl
Slide 9: 2Q24 Key Financial Highlights
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 2Q24 Key Financial Highlights Highly attractive SaaS model with combination of scale, growth and profitability $ in millions 9 (1) See appendix for definition and non-GAAP reconciliations. Adjusted Free Cash Flow Z00 FCF Conversion To
Slide 10: Strong Growth
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Strong Growth $ in millions $42.7 $44.4 $46.5 $48.1 $49.5 2Q23 3Q23 4Q23 1Q24 2Q24 Revenue 10 (1) (1) (1) $(4.1) Gross Profit and Adjusted Gross Profit (1) (1) See appendix for non-GAAP reconciliations. $28.5 $29.9 $30.9 $31.9 $33.5 $
Slide 11: Improving Profitability
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Improving Profitability 66.7% 67.3% 66.4% 66.3% 67.7% 67.3% 68.0% 66.9% 67.8% 68.5% 2Q23 3Q23 4Q23 1Q24 2Q24 Gross Margin Adjusted Gross Margin Gross Margin and Adjusted Gross Margin (1) 11 (1) (1) (1) $(4.1) Net Income Margin and Adj
Slide 12: Improving Profitability
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Improving Profitability 12 (1) See appendix for non-GAAP reconciliations. (1) (1) $(4.1) $1.0 $2.7 $0.9 $-0.8 $2.5 $8.0 $8.2 $9.8 $9.2 $10.1 2Q23 3Q23 4Q23 1Q24 2Q24 Net Income Adjusted EBITDA $6.0 $12.1 $6.6 $1.5 $7.3 $3.8 $9.5 $4.3
Slide 13: Organic client growth and expansion continues to scale
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. $171.2 $177.9 $185.1 $190.5 $195.7 2Q23 3Q23 4Q23 1Q24 2Q24 101.7% 102.4% 102.1% 102.9% 103.0% 2Q23 3Q23 4Q23 1Q24 2Q24 Organic client growth and expansion continues to scale 13 827 842 865 868 879 2Q23 3Q23 4Q23 1Q24 2Q24 $212 $217 $
Slide 14: Front Book + Back Book = Total Revenue Growth
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Front Book + Back Book = Total Revenue Growth 14 Front Book = Onboarding Of New Logos Back Book = Growth From Our Existing Customer Base 20.9% 16.4% 13.4% 14.2% 14.8% -4.0% -3.1% 1.3% 3.1% 1.0% 16.9% 13.3% 14.7% 17.3% 15.8% 2Q23 3Q23
Slide 15: 2024 Guidance
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 2024 Guidance 15 FCF Conversion is adjusted Free Cash Flow divided by Adjusted EBITDA. Adjusted EBITDA guidance excludes stock-based compensation of $19-20 million for the full year of 2024, of which we estimate approximately 1/3 occu
Slide 16: Medium Term Guidance (2025 - 2027)
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Medium Term Guidance (2025 - 2027) 16 Financial Metrics No Change Annual Revenue Growth 20-22% Annual Adjusted EBITDA Margin Expansion 200-400 bps Annual FCF Conversion Expansion 300-500 bps These statements are forward-looking and ac
Slide 17: Appendix
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Appendix
Slide 18: Consolidated Balance Sheets
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. ENFUSION, INC. CONSOLIDATED BALANCE SHEETS (dollars and shares in thousands, except par value) 18 ASSETS Current assets: Cash and cash equivalents $ 34,447 $ 35,604 Accounts receivable, net 33,672 28,069 Prepaid expenses 4,475 5,009 O
Slide 19: Consolidated Statements of Operations
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. ENFUSION, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (dollars and shares in thousands, except per share amounts) (Unaudited) 19 REVENUES: Platform subscriptions $ 45,794 $ 39,610 Managed services 3,223 2,945 Other 438 166 Total revenu
Slide 20: Consolidated Statements of Cash Flows
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. ENFUSION, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (dollars and shares in thousands, except per share amounts) (Unaudited) 20 Cash flows from operating activities: Net income $ 1,786 $ 5,692 Adjustments to reconcile net income to ne
Slide 21: Reconciliations To Non-GAAP Financial Measures
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Reconciliations To Non-GAAP Financial Measures The following table reconciles net income to adjusted EBITDA: The following table reconciles gross profit to adjusted gross profit: 21 1 For the three months ended June 30, 2023, includes
Slide 22: Reconciliations To Non-GAAP Financial Measures
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Reconciliations To Non-GAAP Financial Measures The following table reconciles operating cash flow to adjusted free cash flow: The Company’s stock-based compensation expense was recognized in the following captions within the consolida
Slide 23: Reconciliations To Non-GAAP Financial Measures
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Reconciliations To Non-GAAP Financial Measures The following table reconciles net income to adjusted net Income which is used to calculate adjusted diluted EPS: 23 1 Per share amounts are based on a weighted average number of shares o
Slide 24: Definitions
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Definitions OCF Margin Operating Cash Flow Margin represents net cash provided from operating activities divided by total net revenues. We believe OCF Margin is an important metric because it indicates our ability to convert sales int
Slide 25: Definitions Continued
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Definitions Continued Adjusted Net Income and Adjusted Diluted EPS Adjusted Net Income represents net income adjusted to exclude stock-based compensation expense, the effect of foreign currency fluctuations, certain non-recurring item